|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cases of HD were analyzed by Southern blot hybridization, using DNA probes that detect the major and minor breakpoint cluster regions and a 5'bcl-2 breakpoint region recently cloned and found to be involved in B-cell chronic lymphocytic leukemia, and by the polymerase chain reaction (PCR), using oligonucleotides capable of amplifying and detecting the major breakpoint region (mbr) and minor cluster region (mcr) breakpoint regions in t(14;18). bcl-2 translocations were not detected in any of the 34 cases of HD by Southern blot hybridization or by PCR.
|
1632463 |
1992 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of the methylation status of the bcl-2 gene using the isoschizomers Msp I and Hpa II, and a probe corresponding to the first major exon of the gene showed complete demethylation of both copies of the bcl-2 gene in a region corresponding to a 2.4-kb Msp I fragment in all 20 cases of B-CLL.
|
8104532 |
1993 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we have attempted a conclusive definition of the involvement of dominantly acting oncogenes (Bcl-1 and Bcl-2) and tumor suppressor loci (p53, 6q-) in 100 cases of B-CLL selected for their CD5 positivity and Rai's stage (0 to IV).
|
8203469 |
1994 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we examined 170 cases of B-cell chronic lymphocytic leukemia (B-CLL), 7 cases of B-cell prolymphocytic leukemia (B-PLL), 25 cases of hairy cell leukemia (HCL) and 22 cases of splenic lymphoma with villous lymphocytes (SLVL) with defined cytogenetic abnormalities by DNA blot using both 5' and 3' BCL2 probes to search for rearrangement of the BCL2 locus.
|
8204892 |
1994 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The in vitro rescue from death induced by IL-8 is reflected by an increased expression of bcl-2 mRNA in B-CLL cases incubated in the presence of IL-8.
|
8639799 |
1996 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated the relationship among chemosensitivity to drug-induced apoptosis in vitro, the presence of p53 gene mutations, and the expression of bcl-2 and bax proteins in B-cells from B-cell chronic lymphocytic leukemia (B-CLL) patients.
|
8649796 |
1996 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia.
|
8943893 |
1996 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Incidence of 5' bcl-2 rearrangement in patients with B cell chronic lymphocytic leukemia from India.
|
8947590 |
1996 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, exposure of cells from three patients with B-CLL to bFGF showed an upregulation of bcl-2 protein after 4-8 h. Our data demonstrate that bFGF upregulates the expression of bcl-2 in these cells, suggesting that this increase in bcl-2 expression may play a role in the delay of fludarabine-induced apoptosis.
|
9009090 |
1997 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Drug-induced apoptosis in B-CLL cells was inversely related to Bcl-2/Bax ratios.
|
9328155 |
1997 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53.
|
9459175 |
1997 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine.
|
9613987 |
1998 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.
|
10576505 |
1999 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore Bcl-2 antisense oligonucleotides might be useful in the treatment of B-CLL.
|
10583267 |
1999 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
|
11472347 |
2001 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
This increased in vitro cytotoxicity demonstrates a proof of the concept that a combination of Bcl-2 antisense oligonucleotides with conventional chemotherapeutic drugs may elicit an enhanced therapeutic effect in B-CLL and should therefore be considered for further investigation in the form of a clinical trial.
|
11699414 |
2001 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our previous work demonstrated that antisense oligonucleotides complementary to Bcl-2 mRNA sequences were able to reduce Bcl-2 protein expression in B-cell chronic lymphocytic leukaemia (B-CLL) cells.
|
12481899 |
2002 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
All B-CLL cases were bcl-2 protein positive.
|
12584586 |
2002 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia.
|
14510944 |
2003 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, several Bcl-2 family genes are regulated during B-CLL spontaneous apoptosis and their relative levels may contribute to in vivo progression of the disease.
|
14975737 |
2004 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.
|
15291360 |
2004 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Exposure of B-CLL cells to honokiol resulted in up-regulation of Bcl2-associated protein (Bax) and down-regulation of the expression of the key survival protein myeloid-cell leukemia sequence 1 (Mcl-1), which is associated with response to treatment in B-CLL patients.
|
15802533 |
2005 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased expression of B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) and myeloid cell leukemia sequence 1 (MCL1) proteins and increased staining of Annexin V-positive cells showed that inhibition of FGFR3 induces apoptosis.
|
15897243 |
2005 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The BCL2-938AA genotype is associated with increased Bcl-2 expression and a novel unfavorable genetic marker in patients with B-CLL.
|
16960146 |
2007 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, selective down-regulation of GLI1 by antisense oligodeoxynucleotides (GLI1-ASO) results in decreased BCL2 expression and cell survival, suggesting that GLI1 may regulate BCL2 and, thereby, modulate cell survival in B-CLL.
|
19074837 |
2008 |